GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Knights plunges after profit warning

Tue, 22nd Mar 2022 11:50

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Pebble Group PLC, up 17% at 105.60 pence, 12-month range 85.00p-169.87p. The technology and services promotional products supplier delivers strong performance in 2021, expecting further significant growth opportunities ahead. For 2021, Pebble posts pretax profit GBP9.3 million, up from GBP5.0 million in 2020 on revenue of GBP115.1 million, up from GBP82.4 million. Says 2022 has started well and in line with expectations and looks forward to the year ahead and beyond with confidence.

----------

AIM - LOSERS

----------

Knights Group Holdings PLC, down 48% at 191.44p, 12-month range 188.00p-472.00p. The legal and professional services provider warns Omicron variant and recent macro conditions have slowed growth to a greater extent than anticipated. For year ending April 30, expects adjusted pretax profit - which strips out exceptional and other one-off items - to be GBP18 million. Revenue is forecast to be around GBP126 million. "We have also seen a softening in business confidence, possibly due to concerns around the strength of the economy, such that there has been a slowdown in corporate work," company says.

----------

Diurnal Group PLC, down 41% at 19.63p, 12-month range 17.20p-97.97p. The pharmaceutical company warns further financing will be required if it is to reach sustainable profitability. For six months to December 31, pretax loss widens to GBP9.2 million from loss of GBP5.2 million year before on revenue of GBP2.1 million from GBP1.2 million. Says further financing will be required prior to reaching sustainable profitability. "This requirement for additional financing represents a material uncertainty that may cast significant doubt upon the group's and parent company's ability to continue as a going concern," it says.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
11 Oct 2021 19:51

TRADING UPDATES: Baron Oil boosts P2478 stake amid Upland farmout pact

TRADING UPDATES: Baron Oil boosts P2478 stake amid Upland farmout pact

Read more
14 Sep 2021 17:46

TRADING UPDATES: Strong annual results from Springfield, Fiske

TRADING UPDATES: Strong annual results from Springfield, Fiske

Read more
13 Sep 2021 20:23

IN BRIEF: Diurnal's Efmody adrenal treatment launches in UK

IN BRIEF: Diurnal's Efmody adrenal treatment launches in UK

Read more
7 Sep 2021 16:25

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
1 Sep 2021 19:34

TRADING UPDATES: Power Metal hits "bullseye"; Instem makes acquisition

TRADING UPDATES: Power Metal hits "bullseye"; Instem makes acquisition

Read more
28 Jul 2021 18:07

TRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident

TRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident

Read more
12 Jul 2021 10:10

Diurnal agrees special protocol with FDA for Chronocort study

(Sharecast News) - Specialty pharmaceutical company Diurnal announced on Monday that the US Food and Drug Administration (FDA) has agreed a special protocol assessment (SPA) for 'Chronocort', or modified-release hydrocortisone, for the design, endpoints and statistical analysis approach of a pivotal study of the product, for the treatment for congenital adrenal hyperplasia (CAH).

Read more
2 Jul 2021 10:02

Diurnal gets UK approval for 'Efmody' treatment

(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Friday that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for 'Efmody', or hydrocortisone modified-release hard capsules, as treatment for adult and adolescent patients with the rare congenital adrenal hyperplasia (CAH) condition.

Read more
2 Jul 2021 10:01

Diurnal gets UK approval for Efmody drug following EU authorisation

Diurnal gets UK approval for Efmody drug following EU authorisation

Read more
29 Jun 2021 17:10

TRADING UPDATES: Gaming Realms BetMGM deal; Argo bitcoin-backed loan

TRADING UPDATES: Gaming Realms BetMGM deal; Argo bitcoin-backed loan

Read more
1 Jun 2021 20:24

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

Read more
28 May 2021 19:41

TRADING UPDATES: Odyssean IT swings to profit; BMO Cap ups dividend

TRADING UPDATES: Odyssean IT swings to profit; BMO Cap ups dividend

Read more
12 May 2021 15:30

IN BRIEF: Diurnal extends Citrine licensing deal for Efmody in China

IN BRIEF: Diurnal extends Citrine licensing deal for Efmody in China

Read more
23 Apr 2021 12:56

IN BRIEF: Diurnal gets another patent for adrenal insufficiency asset

IN BRIEF: Diurnal gets another patent for adrenal insufficiency asset

Read more
23 Apr 2021 10:31

Diurnal granted European patent for Alkindi

(Sharecast News) - Hormonal disease-focussed speciality pharmaceutical company Diurnal Group announced the grant of a patent for 'Alkindi', or hydrocortisone granules in capsules for opening, by the European Patent Office on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.